Clinical TrialJun 12, 2026, 04:02 PM
Rhythm Pharma to Discuss Interim Phase 2 Setmelanotide PWS Results June 13
AI Summary
Rhythm Pharmaceuticals announced it will host a live conference call and webcast on Saturday, June 13, to discuss interim six-month results from its Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome (PWS). The discussion will feature David Meeker, M.D., Chairman, President and CEO, alongside Jennifer Miller, M.D., Pediatric Endocrinology, University of Florida College of Medicine. Setmelanotide is an MC4R agonist currently approved for other rare neuroendocrine diseases.
Key Highlights
- Rhythm Pharmaceuticals to host a conference call and webcast on June 13 at 9:00 a.m. ET.
- The call will discuss interim six-month results from the Phase 2 trial of setmelanotide.
- The Phase 2 trial is evaluating setmelanotide in patients with Prader-Willi syndrome (PWS).
- CEO David Meeker and Dr. Jennifer Miller will present and discuss the data.
- A webcast of the call will be available on the company's investor relations website.
Price Impact
More from RYTM